Phase I safety and immunogenicity study of a Brazilian serogroup B vaccine

R Menezes Martins1, A R S Périssé2, L A B Camacho2

  • 1Clinical Advisory Unit, Bio-Manguinhos/Fiocruz, Rio de Janeiro, RJ, Brazil.